Published on : Nov 14, 2016
ALBANY, NY, Nov 14, 2016: The 161-page research study, titled “Global Gastrointestinal Drug Market to 2022 - Pipeline Characterized by Emerging Biologic Therapies, While TNF Inhibitors and PPIs Continue to Dominate Therapy Landscape,” offers a thorough analysis of the market, focusing on key drivers, latest trends, and limitations. Furthermore, the research study helps in understanding the present commercial and clinical landscape of the global gastrointestinal drug market by providing information related to disease diagnosis, disease pathogenesis, and several treatment options that are available at each diagnosis stage.
The research study has further provided vital information of the global market related to the key marketed products, pipeline landscape assessment, and multi-scenario market forecast. In addition, a detailed analysis of the companies and their positioning have been presented in the research study. According to the research study, in 2015, the global market for gastrointestinal drugs was valued at US$35.7 bn and is estimated to reach a value of US$48.4 bn by the end of 2022. The market is expected to register a steady 4.45% CAGR between 2016 and 2022.
The rising prevalence of gastrointestinal disorders and the latest approved premium products are some of the primary factors boosting the demand for gastrointestinal drugs and therapeutics. Additionally, the promising late-stage products, which comprises a large number of biologic therapies is estimated to augment the growth of the overall market throughout the forecast period. The increasing consumption of biologics and development of novel therapies making use of innovative technologies are further estimated to contribute significantly towards the growth of the market.
Click to get more details with TOC in a PDF Format: http://www.researchmoz.us/enquiry.php?type=S&repid=855887
The rising consumption of OTC medications, and discontinuation of several drugs that are under development are some of the key factors anticipated to restrict the growth of the market in the forecast period. Nevertheless, the emergence of biosimilars, rise in self-medication, and the rising focus on regenerative medicines are expected to offer several opportunities for the players operating in the market. These factors are projected to accelerate the growth of the global gastrointestinal drug market in the next few years.
The global market for gastrointestinal drugs is highly fragmented in nature with the presence of a large number of small-scale and large-scale vendors operating in the market worldwide. Some of the leading players operating in the market are Johnson & Johnson, Alexion, AstraZeneca, Allergan, Celgene, Takeda, and AbbVie. These players are focusing on research development activities in order to increase the number of in their pipeline and attain a dominating position across the globe. To provide a clear picture of the market, the research study offers a thorough analysis of these players, including information related to their product portfolio, business strategies, and financial overview.
To order report Call USA – Canada Toll Free: 866-997-4948 or send an email on firstname.lastname@example.org